• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.net
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Equity Research Coverage

VASRO GmbH > Press > Equity Research Coverage

Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace

  • September 11, 2026
  • Equity Research Coverage
VASRO has published an update report on Ainos, Inc. following two company announcements: a dataset milestone on 13 August and three Japanese robotics patents on 9 September. Both announcements...
Continue Reading

Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33

  • September 7, 2026
  • Equity Research Coverage
VASRO GmbH has published an update report on Baladna Q.P.S.C. (Qatar Stock Exchange: BLDN), reiterating its BUY recommendation with a target price of QAR 2.33 per share, revised from...
Continue Reading

Sirnaomics Ltd.: Every Approved siRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer. VASRO Initiates Coverage With BUY

  • September 7, 2026
  • Equity Research Coverage
VASRO GmbH has initiated coverage of Sirnaomics Ltd. (HKEX: 2257) with a BUY recommendation and a target price of HK$7.07 per share. Sirnaomics develops siRNA medicines, drugs that silence...
Continue Reading

Zaptec ASA: Europe’s Largest AC Charging Brand, With the Service Layer Priced at Zero – VASRO Initiates Coverage With BUY

  • August 31, 2026
  • Equity Research Coverage
VASRO has initiated equity research coverage of Zaptec ASA (Oslo Børs: ZAP) with a BUY recommendation and a target price of NOK 72.00 per share. Against the NOK 50.30...
Continue Reading

Spinneys 1961 Holding PLC: The Estate Grew 17%, Demand Did Not — First Half 2026 Update

  • August 12, 2026
  • Equity Research Coverage
VASRO has published an update report on Spinneys 1961 Holding PLC following the company’s first-half 2026 results. The central message is not that the growth story has broken. It...
Continue Reading

Ainos, Inc.: 613 Million Records, and a Cost Base That Did Not Move — First Half 2026 Update

  • August 7, 2026
  • Equity Research Coverage
VASRO has published an update report on Ainos, Inc. following the company’s first-half 2026 results. The central message is not that financial scale has arrived. It has not. The...
Continue Reading

Baladna: From Qatar Dairy Leader to Regional Food-Security Platform

  • August 5, 2026
  • Equity Research Coverage
VASRO has initiated equity research coverage of Baladna Q.P.S.C. with a BUY recommendation and a target price of QAR 2.43 per share. Compared with the QAR 1.21 ex-rights reference...
Continue Reading

Luberef Reports Record H1 2026 Earnings as Base Oil Margins Drive Cash Flow and Higher Valuation

  • August 5, 2026
  • Equity Research Coverage
VASRO has published an updated equity research report on Saudi Aramco Base Oil Company – Luberef, maintaining its BUY recommendation and raising the target price from SAR 136.00 to...
Continue Reading

Ainos, Inc.: AI Nose Starts Reading the Breath Itself in New Emergency-Medicine Study at National Taiwan University

  • June 22, 2026
  • Equity Research Coverage
VASRO has published an update report on Ainos, Inc. following the company’s announcement of a one-year research program with National Taiwan University. The report, titled “AI Nose Starts Reading...
Continue Reading

Ainos, Inc.: AI Nose Enters Live Hospital Emergency-Room Deployment at NTUH

  • June 5, 2026
  • Equity Research Coverage
VASRO has published an update report on Ainos, Inc. following the company’s announcement of an IRB-approved research program with National Taiwan University Hospital. The report, titled “AI Nose Enters...
Continue Reading

Posts pagination

1 2 3 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
Sirnaomics Ltd.: Every Approved siRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer. VASRO Initiates Coverage With BUY September 7, 2026
Zaptec ASA: Europe’s Largest AC Charging Brand, With the Service Layer Priced at Zero – VASRO Initiates Coverage With BUY August 31, 2026
Spinneys 1961 Holding PLC: The Estate Grew 17%, Demand Did Not — First Half 2026 Update August 12, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • Info@vasro.net
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.